Inflectra, in combination with methotrexate, is indicated for the reductions of signs and symptoms as well as the improvement in physical function in adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate. Adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.
In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been deomnstrated (see section 5.1).1
Post marketing data of 4,393 patients has illustrated that the safety profile appears consistent with clinical studies for CT-P13 and reference infliximab, supporting the favourable risk / benefit balance for CT-P13 treatment.2
Please see the link for Inflectra® (infliximab) prescribing information at the top of the page, and refer to section 4.8 for a summary of the safety profile.
Learn about the clinical evidence supporting the use of Inflectra in patients with rheumatoid arthritis
Learn about the dosing and administration of Inflectra in patients with rheumatoid arthritis
Find out more
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020